Galactosylated nanocrystallites of insoluble anticancer drug for liver-targeting therapy: An in vitro evaluation

Nanomedicine

Volumn 5, Issue 4, 2010, Pages 589-596

  Wei, Wei ^a,b   Yue, Zhan Guo ^a,b   Qu, Jian Bo ^a,c   Yue, Hua ^a,b   Su, Zhi Guo ^a   Ma, Guang Hui ^a  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c CHINA UNIVERSITY OF PETROLEUM   (China)

Author keywords

10 Hydroxycamptothecin; Anticancer; Asialoglycoprotein receptor; Drug delivery; Nanocrystallites

Indexed keywords

10 HYDROXYCAMPTOTHECIN; CHITOSAN; NANOCRYSTAL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CELL TRANSPORT; CELL VIABILITY; CYTOTOXICITY; DRUG FORMULATION; DRUG TARGETING; FEASIBILITY STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; LIVER CELL CARCINOMA; MULTICENTER STUDY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLOW CYTOMETRY; GALACTOSE; HUMANS; LIVER NEOPLASMS; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOSTRUCTURES; SOLUBILITY;

EID: 77953396145     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.27     Document Type: Article

References (29)

1. Lipinski C: Poor aqueous solubility - an industry wide problem in drug discovery. Am. Pharm. Rev. 5, 82-85 (2002).
2. Lipinski CA: Drug-like properties and the cause of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235-249 (2000).
3. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26 (2001). (Pubitemid 33653411)
4. Chen MC, Tsai HW, Liu CT et al.: A nanoscale drug-entrapment strategy for hydrogel-based systems for the delivery of poorly soluble drugs. Biomaterials 30, 2102-2111 (2009).
5. Fahr A, Liu X: Drug delivery strategies for poorly water-soluble drugs. Expert Opin. Drug Deliv. 4, 403-416 (2007).
6. Mizoe M, Beppu S, Ozeki T, Okada H: One-step preparation of drug-containing microparticles to enhance the dissolution and absorption of poorly water-soluble drugs using a 4-fluid nozzle spray drier. J. Control. Release 120, 205-210 (2007).
7. Yi T, Wan JL, Xu HB, Yang XL: Controlled poorly soluble drug release from solid self-microemulsifying formulations with high viscosity hydroxypropylmethylcellulose. Eur. J. Pharm. Sci. 34, 274-280 (2008).
8. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R: Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760 (2007).
9. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y: Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 49, 1465-1469 (1989).
10. Hatefi A, Amsden B: Camptothecin delivery methods. Pharm. Res. 19, 1389-1399 (2002).
11. Thomas CJ, Rahier NJ, Hecht SM: Camptothecin: current perspectives. Bioorg. Med. Chem. 12, 1585-1604 (2004).
12. Garcia-Carbonero R, Supko JG: Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res. 8, 641-661 (2002).
13. Min KH, Park P, Kim YS et al.: Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J. Control. Release 127, 208-218 (2008).
14. Kast CE, Bernkop-Schnurch AB: Thiolated polymers-thiomers: development and in vitro evaluation of chitosan-thioglycolic acid conjugates. Biomaterials 22, 2345-2352 (2001).
15. Kassab R, Parrot-Lopez H, Fessi H, Menaucourt J, Bonaly R, Coulon J: Molecular recognition by kluyveromyces of amphotericin B-loaded, galactose-tagged, poly (lactic acid) microspheres. Bioorg. Med. Chem. 10, 1767-1775 (2002).
16. Uggeri J, Gatti R, Belletti S et al.: Calcein-AM is a detector of intracellular oxidative activity. Histochem. Cell Biol. 122, 499-505 (2004).
17. Poole CA, Brooks NH, Gilbert RT et al.: Detection of viable and non-viable cells in connective tissue explants using the fixable fluoroprobes 5-chloromethylfluorescein diacetate and ethidium homodimer-1. Connect. Tissue Res. 33, 233-241 (1996).
18. Managit C, Kawakami S, Yamashita F, Hashida M: Uptake characteristics of galactosylated emulsion by HepG2 hepatoma cells. Int. J. Pharm. 301, 255-261 (2005).
19. Wang SL, Yu FB, Jiang TY, Sun CS, Wang T, Zhang JH: Design and synthesis of novel galactosylated polymers for liposomes as gene drug carriers targeting the hepatic asialoglycoprotein receptor. J. Drug Target. 16, 233-242 (2008).
20. Kim TH, Park IK, Nah JW, Choi YJ, Cho CS: Galactosylated chitosan/DNA nanoparticles prepared using water-soluble chitosan as a gene carrier. Biomaterials 25, 3783-3792 (2004).
21. Gao S, Chen J, Dong L, Ding Z, Yang YH, Zhang J: Targeting delivery of oligonucleotide and plasmid DNA to hepatocyte via galactosylated chitosan vector. Eur. J. Pharm. Biopharm. 60, 327-334 (2005).
22. Conner SD, Schmid SL: Regulated portals of entry into the cell. Nature 422, 37-44 (2003).
23. Gratton SEA, Ropp PA, Pohlhaus PD et al.: The effect of particle design on cellular internalization pathways. Proc. Natl Acad. Sci. USA 105, 11613-11618 (2008).
24. Khalil IA, Kogure K, Akita H, Harashima H: Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol. Rev. 58, 32-45 (2006).
25. Mousavi SA, Malerød L, Berg T, Kjeken R: Clathrin-dependent endocytosis. Biochem. J. 377, 1-16 (2004).
26. O'Driscoll L: Mechanisms of drug sensitivity and resistance in cancer. Curr. Cancer Drug Targets 9, 250-251 (2009).
27. Livingston DM, Silver DP: Cancer: crossing over to drug resistance. Nature 451, 1066-1067 (2008).
28. Shiraishi T, Hamzavi R, Nielsen PE: Targeted delivery of plasmid DNA into the nucleus of cells via nuclear localization signal peptide conjugated to DNA intercalating bis- and trisacridines. Bioconjug. Chem. 16, 1112-1116 (2005).
29. Jeon O, Lim HW, Lee M, Song SJ, Kim BS: Poly(l-lactide-co-glycolide) nanospheres conjugated with a nuclear localization signal for delivery of plasmid DNA. J. Drug Target. 15, 190-198 (2007).